Latest Breaking News On - Suhail nurbhai - Page 1 : comparemela.com

First-in-human clinical trial for disease-modifying Parkinson s treatment commences

First-in-human clinical trial for disease-modifying Parkinson s treatment commences
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Suhail nurbhaiShenaz baghaMission therapeuticsUnited kingdom based

Mission Therapeutics moves kidney disease drug to phase 2 after FDA approval

Mission Therapeutics, a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to proceed with a phase 2 trial for its kidney treatment MTX652.

United statesSuhail nurbhaiAnker lundemosePaul thompsonMission therapeuticsNorth americaIschaemic reperfusion injuryClinical developmentMarkets amp regulationsLinical evolutionKidney diseaseClinical trialPhase 2

Mission Therapeutics gets FDA approval to continue trial with new AKI drug

Mission Therapeutics gets FDA approval to continue trial with new AKI drug
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSuhail nurbhaiPaul thompsonBymarke neumannGina brockenbroughMission therapeuticsNorth america

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

/PRNewswire/ Mission Therapeutics ("Mission" or the "Company"), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today.

United statesUnited kingdomSuhail nurbhaiPaul thompsonAnker lundemoseRoche venture fundDrug administrationMission therapeuticsIp groupPrnewswire mission therapeuticsInvestigational new drugAcute kidney injuryNorth americaChief executive officerChief medical officerChief scientific officer

IP : Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury -December 14, 2023 at 12:44 pm EST

14 Dec 2023 - Mission gains clearance from US FDA for Phase II trial of MTX652 after it receives official approval of its Investigational New Drug application .

United statesMary clarkStephen adamsPaul thompsonAnker lundemoseSuhail nurbhaiMission therapeutics ltdDrug administrationMission therapeuticsIp groupStrategic communicationsRoche venture fundInvestigational new drugAcute kidney injuryNorth americaChief executive officer